Founded Year

2013

Stage

Corporate Minority | Alive

Total Raised

$150.8M

Last Raised

$75M | 1 mo ago

About CathWorks

CathWorks develops image-based functional flow reserve (FFR) measurement tools. CathWorks's angiogram-based FFR (FFRangio) improves real-time functional assessment leading to treatment decisions and makes coronary catheterization procedures safer, shorter, more accurate, and more comprehensive. It was founded in 2013 and is based in Kfar-Saba, Israel.

CathWorks Headquarter Location

3 Rapaport St

Kfar-Saba, 4465141,

Israel

CathWorks's Product Videos

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CathWorks's Products & Differentiation

See CathWorks's products and how their products differentiate from alternatives and competitors

  • FFRangio System

    The CathWorks FFRangio™ System uses AI and brings you the definitive benefits of FFR on a quick, non-invasive platform, complete with accurate multi-vessel physiologic and anatomic insights to optimize and confirm PCI decisions for more patients.

    Differentiation

    The CathWorks FFRangio™System delivers accurate multi-vessel FFR measurements without the need for invasive pressure wires or drug stimulation, all in a few minutes inside the cath lab. The non-inva… 

Expert Collections containing CathWorks

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CathWorks is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

11,738 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,900 items

CathWorks Patents

CathWorks has filed 25 patents.

The 3 most popular patent topics include:

  • Vascular diseases
  • Cardiac procedures
  • Cardiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/23/2020

8/9/2022

Vascular diseases, Cardiac procedures, Cardiology, Cardiovascular physiology, Vascular procedures

Grant

Application Date

3/23/2020

Grant Date

8/9/2022

Title

Related Topics

Vascular diseases, Cardiac procedures, Cardiology, Cardiovascular physiology, Vascular procedures

Status

Grant

Latest CathWorks News

MPO\'s Most-Read Stories This Week—July 16

Jul 16, 2022

A listing of the most popular items from the past seven days. Michael Barbella, Managing Editor07.16.22 New device reprocessing standards drove the bulk of MPO website traffic this week, as cybervisitors flocked to the site to learn more about a regulatory roadmap being shared by the Association of Medical Device Reprocessors. The organization has published “Global Regulatory Standards for ‘Single-Use’ Medical Device Reprocessing and Remanufacturing,” a tool to help Notified Bodies, Ministries of Health, and regulatory authorities of medical devices to unlock the benefits of reprocessing for hospitals and health systems worldwide. The report includes all known regulations, standards, and guidances that govern the practice of reprocessing (known as remanufacturing in Europe), worldwide. Runner-up to the reprocessing roadmap was an exclusive contribution from Sweetch CEO Yoni Nevo on leveraging SaMD (software as a medical device) and digital therapeutics (DTx) to help patients with chronic conditions adhere to their treatment programs. "SaMD and DTx solutions are promising, but they are only truly effective when their engagement with patients is precise and personalized," Nevo writes. "It is insufficient for an SaMD or DTx solution to prompt a patient to take their medication when they are driving, or to go for a walk when they are in a meeting. For apps to be effective, they need to hyper-personalize the patient’s experience." Also garnering page views this past week was FDA authorizations for—coincidentally (or not)—AI-based MRI software and a digital therapeutic. Philips won FDA 510(k) clearance for its SmartSpeed artificial intelligence (AI)-powered MR acceleration software, while Renovia earned the agency's clearance for its leva pelvic health system as a first-line treatment for chronic fecal incontinence (FI) in women. leva was granted FDA breakthrough status in 2021 and had  previously been FDA-cleared  to treat stress, mixed, and mild-to-moderate urinary incontinence (UI) in women. leva helps women strengthen pelvic floor muscles, including the puborectalis, which acts as a “sling” around the rectum and vagina and contributes directly to FI. The prescription digital therapeutic (PDT) guides woman through pelvic floor muscle training (PFMT) via a small vaginal motion sensor and smartphone app. It requires five minutes of training a day. Philips' AI reconstruction algorithm,  meanwhile, is used at the MR signal’s front end to remove the noise and preserve details while enabling k-space data consistency check for trustworthy AI. It increases resolution up to 65% and achieves up to 3 times faster scanning times compared to conventional MR scans. Medtronic's partnership with CathWorks attracted website traffic as well. The company is investing up to $75 million and co-promoting CathWorks’ FFRangio system in the United States, Europe, and Japan, where it’s currently available. In a separate agreement, Medtronic was given the option to acquire CathWorks once certain undisclosed milestones are met.

CathWorks Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CathWorks Rank

  • When was CathWorks founded?

    CathWorks was founded in 2013.

  • Where is CathWorks's headquarters?

    CathWorks's headquarters is located at 3 Rapaport St, Kfar-Saba.

  • What is CathWorks's latest funding round?

    CathWorks's latest funding round is Corporate Minority.

  • How much did CathWorks raise?

    CathWorks raised a total of $150.8M.

  • Who are the investors of CathWorks?

    Investors of CathWorks include Medtronic, Deerfield Management, BioStar Capital, Pontifax, Quark Venture and 6 more.

  • Who are CathWorks's competitors?

    Competitors of CathWorks include Medipixel and 3 more.

  • What products does CathWorks offer?

    CathWorks's products include FFRangio System.

You May Also Like

Sensome Logo
Sensome

Sensome develops micro-sensor technology for smart medical devices. Sensome's sensing technology can be integrated with any medical device to reliably identify biological tissues in contact with the device. The technology combines micrometric impedance sensors that communicate wirelessly outside the body and machine learning algorithms for accurate and predictive real-time analysis.

N
Nesos

Nēsos aims to transform disease treatment by developing brain interfaces that help the brain regain control of immune function.

T
Triple Jump

Triple Jump develops a small insulin pump patch that is placed on the patient’s body. The patch has mobile connectivity capabilities and will be included in a future artificial pancreas system.

P
Presidio Medical

Presidio Medical was founded in 2017 and is headquartered in South San Francisco. The clinical-stage, privately-held medical device company, is developing a transformational neuromodulation technology platform with a first indication in the treatment of chronic pain.

I
Intelligent Implants

Intelligent Implants is developing electrotherapeutic devices to treat disease and aid recovery in bone and other tissues. The company uses data, engineering, and biologics to bring new, active and connected medical devices to healthcare. These integrated devices facilitate treatment for the patient, as well as, decision making for the healthcare professional.

Cardionomic Logo
Cardionomic

Cardionomic addresses Acute Decompensated Heart Failure's root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.